Skip to main content

Table 1 Patients' baseline characteristics: XELOX and FOLFOX4 groups

From: Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement

  

XELOX

(n = 30)

FOLFOX4

(n = 30)

Statistical significance

p-value

Male, %

 

57

57

 

Chinese ethnicity, %

 

94

100

 

Mean age, years

 

63.9

61.9

0.936*

Mean weight, kg

 

61.6

59.8

0.544*

Mean height, cm

 

165.4

162.6

0.281*

Mean body surface area, m2

 

1.65

1.62

0.555*

ECOG PS, % of patients

0

34

30

0.860‡

 

1

53

53

 
 

2

4

4

 

Alkaline phosphatase, % abnormal

 

20

17

0.741‡

No. of metastatic sites, % of patients

1

57

53

0.822‡

 

2

33

37

 
 

≥3

10

10

 

Liver metastases present, % of patients

 

77

50

0.034‡

Status at August 2009, % surviving

 

67

47

0.121‡

  1. * T-test, ‡ Kruskal-Wallis rank test.